Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Endothelial Cells Collection Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Serial Phlebotomy in Voluntary Blood Donors

NCT02762422
View directory record Official record
Conditions
Atherosclerosis
Interventions
Phlebotomy
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Oct 20, 2026, 4:51 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

NCT05627635
View directory record Official record
Conditions
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8
Interventions
Balstilimab, Bevacizumab, Biospecimen Collection, Botensilimab, Computed Tomography, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography, X-Ray Imaging
Biological · Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Recruiting Phase 3 Interventional

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

NCT04181060
View directory record Official record
Conditions
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Bevacizumab, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Osimertinib
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
603
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 425 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Terminated Phase 4 Interventional

A Novel Therapeutic Treatment of Pyoderma Gangrenosum

NCT05120726
View directory record Official record
Conditions
Pyoderma Gangrenosum
Interventions
Dehydrated human amnion/chorion membrane
Biological
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Metairie, Louisiana • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 20, 2026, 4:51 PM EDT
Terminated No phase listed Observational Results available

Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease

NCT03709771
View directory record Official record
Conditions
Renal Cell Carcinoma, Hypertension, Melanoma, Cancer
Interventions
Ambulatory Blood Pressure Measurement
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Oct 20, 2026, 4:51 PM EDT
Recruiting Phase 3 Interventional

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

NCT07271355
View directory record Official record
Conditions
Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Stage IV Appendix Carcinoma AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
Interventions
Bevacizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Magnetic Resonance Imaging, Mitomycin, Questionnaire Administration
Biological · Procedure · Drug + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Goodyear, Arizona • Duarte, California • Irvine, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Phase 1 Interventional

Endothelial Cell Dysfunction in Pulmonary Hypertension

NCT00098072
View directory record Official record
Conditions
Secondary Pulmonary Arterial Hypertension
Interventions
Heart Catheterization
Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Withdrawn Phase 2 Interventional

Effects of Nitric Oxide on the Endothelium During Hemolysis.

NCT03748082
View directory record Official record
Conditions
Endothelial Dysfunction, Hemolysis Intravascular, Cardiovascular Diseases, Cardiovascular Risk Factor
Interventions
Nitric Oxide, Reactive Hyperemia Index, Endothelial Cells Collection
Drug · Diagnostic Test · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 20, 2026, 4:51 PM EDT
Recruiting Phase 4 Interventional

Cholesterol Lowering and Residual Risk in Diabetes, Type 1

NCT05641753
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Evolocumab Cartridge, Atorvastatin Calcium Tablets, Ezetimibe Tablets, 18F-FDG, Angiocatheter 20IV, J-Wire, GlycoCheck Glycocalyx Measurement Software
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 89 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 20, 2026, 4:51 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants

NCT03937817
View directory record Official record
Conditions
Alpha and Beta Thalassemia, Sickle Cell Disease, Malaria, Human Physiology
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Not yet recruiting No phase listed Observational

Vascular Endothelial Inflammation and Health Status In INOCA (VISION-INOCA)

NCT07586241
View directory record Official record
Conditions
Ischemia and Non-obstructive Coronary Arteries
Interventions
Invasive coronary angiography, Coronary Artery Endothelial Cell Sampling, Fitbit, Invasive coronary function testing
Procedure · Device · Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Phase 1 Interventional Results available

Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors

NCT03250832
View directory record Official record
Conditions
Neoplasms
Interventions
TSR-033, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
11
States / cities
Los Angeles, California • Whittier, California • Sarasota, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 20, 2026, 4:51 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Mechanisms of Pregnancy Vascular Adaptations

NCT03806283
View directory record Official record
Conditions
Pre-Eclampsia, Vascular Diseases
Interventions
Omental Biopsy
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

NCT02971501
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8
Interventions
Bevacizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Osimertinib
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
18
States / cities
Los Angeles, California • Pasadena, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

Phosphate Lowering in CKD Trial

NCT02209636
View directory record Official record
Conditions
Chronic Kidney Disease, Cardiovascular Disease
Interventions
Lanthanum carbonate, placebo, Ascorbic Acid, Nitroglycerin, Flow-mediated dilation measurement, Aortic pulse-wave velocity, Endothelial cell collection
Drug · Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 79 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 20, 2026, 4:51 PM EDT
Recruiting Phase 1Phase 2 Interventional

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

NCT03942328
View directory record Official record
Conditions
Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Atezolizumab, Bevacizumab, External Beam Radiation Therapy, Pheresis, Pneumococcal 13-valent Conjugate Vaccine, Therapeutic Autologous Dendritic Cells, Durvalumab, Esophagogastroduodenoscopy, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Biopsy Procedure, Biospecimen Collection
Biological · Radiation · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Results available

Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer

NCT00089609
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Docetaxel, Thalidomide, Prednisone, bevacizumab, polymorphism analysis, immunoenzyme technique, laboratory biomarker analysis, pharmacological study
Drug · Biological · Genetic + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Oct 20, 2026, 4:51 PM EDT
Recruiting Phase 1 Interventional

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

NCT06696768
View directory record Official record
Conditions
Metastatic Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Adenocarcinoma
Interventions
Bevacizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Emavusertib, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
13
States / cities
Gainesville, Florida • Shiloh, Illinois • Fairway, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme

NCT00621686
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
bevacizumab, sorafenib tosylate
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
204
States / cities
Scottsdale, Arizona • Fresno, California • Fort Collins, Colorado + 129 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 20, 2026, 4:51 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Endothelial Cell Gene Networks of CVD

NCT03529916
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
isolation of endothelial cells precursors in blood
Other
Lead sponsor
Tufts University
Other
Eligibility
30 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 20, 2026, 4:51 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)

NCT07083557
View directory record Official record
Conditions
Obesity and Obesity-related Medical Conditions, Diabetes, Atherosclerotic Disease, Heart Failure, MASH, Sarcopenia, Osteoporosis, Hyperparathyroidism, Hypoparathyroidism, Ischemic Heart Disease, Cystic Fibrosis (CF), Chronic Kidney Disease(CKD), Osteopenia, Cachexia
Interventions
Endothelial cell collection
Other
Lead sponsor
Bettina Mittendorfer
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2030
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Blood Collection for Research Related to Certain Diseases Involving Blood Vessels

NCT00047996
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
2
States / cities
Bethesda, Maryland • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Role of Endothelial Function in SCI CVD Risk

NCT06443151
View directory record Official record
Conditions
Spinal Cord Injuries, Cardiovascular Diseases, Endothelial Dysfunction
Interventions
Brachial intra-arterial infusion of vasoactive and antioxidant drugs (acetylcholine, nitroprusside, ascorbic acid), venous occlusion plethysmography, Acetylcholine, Sodium Nitroprusside, Ascorbic acid, venous phlebotomy
Procedure · Drug
Lead sponsor
Craig Hospital
Other
Eligibility
18 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 20, 2026, 4:51 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

PAI-1, tPA, TFPI and HEECs in Uterine Hemostasis

NCT05862805
View directory record Official record
Conditions
Menstrual Bleeding, Heavy
Interventions
Sample Collection and Endometrial Biopsy
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 20, 2026, 4:51 PM EDT